Spots Global Cancer Trial Database for afinitor
Every month we try and update this database with for afinitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) | NCT00790400 | Tuberous Sclero... Lymphangioleiom... | Everolimus (RAD... Everolimus Plac... | 18 Years - | Novartis | |
| Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer | NCT01596140 | Advanced Cancer Solid Tumor | Vemurafenib Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma | NCT01797523 | Endometrial Can... | Metformin Letrozole Everolimus | 18 Years - | M.D. Anderson Cancer Center | |
| Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer | NCT01698918 | Hormone Recepto... | Everolimus Letrozole Exemestane Alcohol-free de... Standard of car... | 18 Years - | Novartis | |
| Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma | NCT01185366 | Kidney Cancer | Everolimus Sunitinib | 18 Years - | M.D. Anderson Cancer Center | |
| Exemestane-RAD001-Metformin | NCT01627067 | Breast Cancer | Everolimus Exemestane Metformin | 18 Years - | M.D. Anderson Cancer Center | |
| Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer | NCT01087554 | Advanced Cancer | Sirolimus Vorinostat Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease | NCT01864070 | Liver Cancer | TheraSphere Everolimus Phone Call | 18 Years - | M.D. Anderson Cancer Center | |
| Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer | NCT01087554 | Advanced Cancer | Sirolimus Vorinostat Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer | NCT01596140 | Advanced Cancer Solid Tumor | Vemurafenib Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer | NCT05108740 | Advanced Hormon... | everolimus | 18 Years - 99 Years | Novartis | |
| Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma | NCT01889420 | Multiple Myelom... | Combination the... | 18 Years - | New Mexico Cancer Care Alliance | |
| LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma | NCT02138929 | Esophageal Canc... | Everolimus LDE 225 | 18 Years - | M.D. Anderson Cancer Center | |
| Safety of Everolimus and Pemetrexed in Lung Cancer Patients | NCT00434174 | Non Small Cell ... | Everolimus Pemetrexed | 18 Years - | Novartis | |
| Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell Carcinoma | NCT01598038 | Renal Cell Carc... | Blood sample | 18 Years - | Centre Francois Baclesse | |
| Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer | NCT02291913 | Breast Cancer | Everolimus Exemestane Tamoxifen Fulvestrant Anastrozole Letrozole Toremifine | 18 Years - | SCRI Development Innovations, LLC | |
| Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer | NCT01068249 | Endometrial Can... | Letrozole RAD001 (Everoli... | 18 Years - | M.D. Anderson Cancer Center | |
| Safety of Everolimus and Pemetrexed in Lung Cancer Patients | NCT00434174 | Non Small Cell ... | Everolimus Pemetrexed | 18 Years - | Novartis | |
| MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer | NCT05108740 | Advanced Hormon... | everolimus | 18 Years - 99 Years | Novartis | |
| RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome | NCT02991807 | PTEN Gene Mutat... PTEN Hamartoma ... | RAD001 Placebo | 5 Years - 45 Years | Boston Children's Hospital | |
| Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell Carcinoma | NCT01598038 | Renal Cell Carc... | Blood sample | 18 Years - | Centre Francois Baclesse | |
| Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance | NCT01197170 | Solid Tumors Advanced Cancer | Anastrozole Bevacizumab Everolimus Sorafenib Erlotinib | 18 Years - | M.D. Anderson Cancer Center | |
| Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer | NCT01596140 | Advanced Cancer Solid Tumor | Vemurafenib Everolimus Temsirolimus | - | M.D. Anderson Cancer Center | |
| Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease | NCT01864070 | Liver Cancer | TheraSphere Everolimus Phone Call | 18 Years - | M.D. Anderson Cancer Center | |
| Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial | NCT01217931 | Kidney Cancer | Pazopanib Bevacizumab Everolimus | 18 Years - | M.D. Anderson Cancer Center | |
| Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer | NCT02291913 | Breast Cancer | Everolimus Exemestane Tamoxifen Fulvestrant Anastrozole Letrozole Toremifine | 18 Years - | SCRI Development Innovations, LLC | |
| Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI | NCT01797120 | Metastatic Brea... | Fulvestrant Everolimus Placebo | 18 Years - | PrECOG, LLC. | |
| LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma | NCT02138929 | Esophageal Canc... | Everolimus LDE 225 | 18 Years - | M.D. Anderson Cancer Center | |
| Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer | NCT01068249 | Endometrial Can... | Letrozole RAD001 (Everoli... | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
